Fulzerasib
CAS No. : 2641747-54-6
(Synonyms: IBI351; GFH925)
| Size | Price | Stock |
|---|---|---|
| 1mg | $197 | In-stock |
| 5mg | $347 | In-stock |
| 10mg | $460 | In-stock |
| 25mg | $770 | In-stock |
| 50mg | $1100 | In-stock |
| 100mg | $1770 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-152848 |
| M.Wt: | 617.07 |
| Formula: | C32H30ClFN6O4 |
| Purity: | >98 % |
| Solubility: | 10 mM in DMSO |
Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905).[1][2].
In Vitro:Fulzerasib covalently inhibits GDP/GTP nucleotide exchange on KRAS G12C (IC50: 29 nM), locking KRAS in its inactive GDP-bound state (RAS-GTP IC50: 74 nM), thereby blocking the KRAS signaling pathway (pERK IC50: 37 nM)[1].
Fulzerasib inhibits the growth of tumor cell lines carrying the KRAS G12C mutation (IC50: 2-20 nM)[1].
In Vivo:Fulzerasib shows strong anti-tumor activity in various models, including the pancreatic cancer cell line MIA Paca-2 CDX, human lung adenocarcinoma NCI-H358 CDX, patient-derived xenograft colon adenocarcinoma SW837 CDX, and lung cancer LU2529 PDX[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Fulzerasib
- Cat. No.:
- HY-152848
- Quantity:
Your information is safe with us.